Monroe Capital Supports Tilia Holdings' Acquisition of Caputo Cheese
Founded in 1978 and headquartered in Melrose Park, IL, Caputo is a value-added processor of high-quality Italian cheeses, including hard cheeses and fresh, soft cheeses, primarily serving the foodservice and food manufacturing sectors. Caputo provides customized aging, flavor formulation, blending and packaging services to a loyal base of blue-chip customers established through their dedication to quality, flavor, and customer service.
About Monroe Capital
Monroe Capital LLC ('Monroe') is a premier asset management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, alternative credit solutions, structured credit, real estate and equity. Since 2004, the firm has been successfully providing capital solutions to clients in the U.S. and Canada. Monroe prides itself on being a value-added and user-friendly partner to business owners, management, and both private equity and independent sponsors. Monroe's platform offers a wide variety of investment products for both institutional and high net worth investors with a focus on generating high quality 'alpha' returns irrespective of business or economic cycles. The firm is headquartered in Chicago and has 11 locations throughout the United States, Asia and Australia.
Monroe has been recognized by both its peers and investors with various awards including Private Debt Investor as the 2024 Lower Mid-Market Lender of the Year, Americas and 2023 Lower Mid-Market Lender of the Decade; Inc.'s 2024 Founder-Friendly Investors List; Global M&A Network as the 2023 Lower Mid-Markets Lender of the Year, U.S.A.; DealCatalyst as the 2022 Best CLO Manager of the Year; Korean Economic Daily as the 2022 Best Performance in Private Debt – Mid Cap; Creditflux as the 2021 Best U.S. Direct Lending Fund; and Pension Bridge as the 2020 Private Credit Strategy of the Year. For more information and important disclaimers, please visit www.monroecap.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
East End deli to open new cafe next week
AN East End deli has announced it is opening a new cafe. Pietro's Deli, located in Bowpark Industrial Estate on Carmyle Avenue, is set to open Mamma Vivienne's Italian Cafe. The new eatery will open its doors on Monday, July 28. READ NEXT: Fashion and homeware brand closes city centre store In a post shared on Facebook, bosses wrote: "Fresh coffee, homemade pasta, crispy pizzas/ focaccias and sweet cannoli await." Fans of the deli, which first opened five years ago selling authentic Italian produce, were delighted by the news. READ NEXT: Cat cafe launces new rehoming charity One person wrote: "Amazing news." Another said: "Looking forward to bringing the kids down." A third person commented: "The best cafe in Glesga."
Yahoo
4 hours ago
- Yahoo
EU court fines Credit Suisse €29 million over foreign exchange cartel
A European Union court on Wednesday imposed a fine of just under €29 million ($34 million) on former bank Credit Suisse, now owned by UBS, for illegal agreements in foreign exchange trading between 2011 and 2012. In 2021 the European Commission had imposed fines totalling €344 million on Credit Suisse and four other major European banks following a cartel investigation. The probe concerned agreements in the spot foreign exchange market - a part of foreign exchange trading in which currencies are exchanged within a short period of time after a transaction is concluded. The EU General Court found the banks' traders had exchanged sensitive information in a professional online chat room, which "distorted free competition." Unlike the other banks involved in the cartel - UBS, Barclays, RBS and HSBC - Credit Suisse decided not to reach a settlement with the commission and instead filed a complaint. In its ruling, the court confirmed Credit Suisse's involvement in the cartel but reduced the initial fine of over €83 million to just under €29 million, arguing the penalty had been calculated incorrectly. The plaintiffs have the right to appeal the decision. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 hours ago
- Business Wire
Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.
PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has secured €200 million in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. These fundings are intended to support the Company's ongoing capital expenditure projects in Cisterna di Latina (Italy) and Fishers (Indiana, U.S.). The financing agreements bolster Stevanato Group's capacity expansion efforts and the scaling of commercial production to support customers' growing biologics programs. CDP has committed €50 million to enhance the production of pre-filled syringes and set-up future capacity for ready-to-use (RTU) cartridges at Stevanato Group's Italian plant in Cisterna di Latina. Additionally, BNL BNP Paribas has provided €100 million, and Banco BPM has contributed €50 million, both aimed at scaling pre-filled syringe production at the company's facilities in North America (Indiana) and Italy, as well as completing the ongoing construction for device manufacturing in Fishers. 'These agreements are an important element to Stevanato Group's financial strategy, allowing us to capitalize on robust customer demand and support the Company's long-term growth objectives,' stated Marco Dal Lago, Chief Financial Officer of Stevanato Group. 'We are committed to supporting our customers' biopharmaceutical programs with our unique value proposition of offering integrated solutions across the pharmaceutical value chain, helping to enable our customers to meet and exceed their program objectives.' BNL BNP Paribas and Cassa Depositi e Prestiti have renewed their support for Stevanato Group to achieve long-term organic growth objectives in its key end-markets. Gianluca Mariani, Head of Industrial Manufacturing, Large Corporate Banking at BNL BNP Paribas: 'Our support for Stevanato Group reflects our commitment to partnering with companies that invest in innovation, sustainability and global expansion. Stevanato Group is a leading example of excellence in its sector, and our goal is to make our domestic and international platforms available to contribute to the growing ambitions of the Company in the coming years.' 'We are proud to once again support the growth plans of Stevanato Group, a leading Italian company active in the pharmaceutical sector, which is strategic for the Country,' stated Marco Roberto Pessione, Head of Corporate Coverage at CDP. 'We firmly believe in the value of companies that invest in research, quality, and sustainable development, and that make a tangible contribution to the growth of the national economy. We remain committed to standing alongside these businesses, providing effective financial instruments to support their growth and consolidation plans both in Italy and internationally.' 'We are proud to support a company like Stevanato Group, a symbol of Italian industrial excellence worldwide, in its solid and innovation-driven growth journey,' said Enrico Lemmo, Head of Corporate Banking North-East at Banco BPM. 'This financing reflects our commitment to backing projects that create value locally while strengthening the international competitiveness of Italian enterprises.' Forward-Looking Statements This press release may include forward-looking statements. The words 'growing,' 'enhancing,' 'intended,' 'are seeing,' 'are committed,' 'achieve,' 'enable,' and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company's plans regarding its presence in the U.S. market, business strategies, the Company's capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements. About Stevanato Group Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: BNL BNP Paribas With more than one hundred years' experience, BNL BNP Paribas is one of the main Italian banking groups and one of the most well-known brands in Italy, where it operates all over the Country. It offers a wide range of products and services to meet the diverse needs of its clients (individuals, businesses, and public administrations). Since 2006, BNL has been part of BNP Paribas, a Group present in 63 countries with approximately 183,000 employees, including over 146,000 in Europe, where it operates in four domestic markets: Belgium, France, Italy, and Luxembourg. BNP Paribas holds key positions in its major business segments: Commercial, Personal Banking & Services; Investment & Protection Services; and Corporate & Institutional Banking. Like the entire Group, BNL BNP Paribas is particularly committed to economic, social, and environmental sustainability; a strategy that epitomizes the Bank's ambition to generate, through its business, a positive impact on clients, employees, and the community, contributing to a more sustainable future. About CDP Cassa Depositi e Prestiti is the National Promotional Institute which has been supporting the Italian economy since 1850. The main goal of CDP is to accelerate the industrial and infrastructural development of Italy to boost its economic and social growth. CDP focuses its activities on sustainable development at local level, supporting the innovation and growth of Italian enterprises, also in the international arena. It partners local authorities, in a financing and advisory capacity, to create infrastructures and improve services of public value. CDP also participates actively in international cooperation initiatives to realize projects in developing countries and emerging markets. Cassa Depositi e Prestiti is entirely financed by private capital, through the issuing of Postal Savings Bonds and Postal Savings Passbooks, and through issues on national and international financial markets. About Banco BPM On 1 January 2017, two large so-called 'popolari' banks, Banco Popolare and Banca Popolare di Milano, merged and transformed into a joint stock company (S.p.A.). The Banco BPM Group was established: a solid entity, with over 20,000 employees, 1,400 branches and around 4 million customers. Banco BPM, which today is Italy's third largest financial services group in terms of assets, has a deeply rooted presence in the regions of Northern Italy, including those with the highest industrial concentration in Europe. A widespread network serving households and businesses, an in-depth knowledge of the markets and innovative solutions underpin the strength of Banco BPM, which is active in various areas of the banking sector – private and investment banking, asset management, bancassurance – also through the Group's subsidiaries. Banco BPM's business model focuses on its people and their skills, enhanced by constant training. The Group operates in the tradition of 'popolari' banks, generating profitability for its shareholders and creating value for all its stakeholders in the areas in which it is present, so as to play a leading role in the sustainable and inclusive development of the country.
